On January 24, 2018, Boston Scientific (BSX) announced an investment deal, including an acquisition option, with Millipede.
Boston Scientific (BSX) has spent ~$89 million on the settlement of lawsuits related mainly to its mesh litigation.
In December 2017, the Tax Cuts and Jobs Act was passed in the US Senate. The healthcare industry has seen the impact of the tax reform.
BSX’s Lotus TAVR (transcatheter aortic valve replacement) system helped it enter the attractive TAVR market space with exceptional opportunity for growth.
On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.
Teva Pharmaceuticals stock rose ~10.5% during the morning of February 15, 2018, before closing at a rise of ~7.7% on the day.
On February 15, TEVA stock rose ~10.5% in pre-market trading on the disclosure of Berkshire Hathaway’s investment of $358 million in the stock at the end of 4Q17.
In 4Q17, Boston Scientific’s (BSX) Rhythm Management segment registered sales of ~$565 million.
Total revenues for AMAG Pharmaceuticals (AMAG) increased to $153.7 million in 3Q17 from $143.7 million in 3Q16.
AMAG’s revenues from Ferahame grew at a higher pace to $26 million in 3Q17 from $22.2 million in 3Q16.
AMAG Pharmaceuticals’ business strategy includes the expansion of its portfolio through licensing and acquisitions of additional pharmaceutical products.
As discussed, The Wall Street Journal recently reported that Walgreens Boots Alliance (WBA) is in acquisition talks with AmerisourceBergen (ABC). The deal, if proposed and completed, would combine America’s largest…
Walgreens Boots Alliance (WBA) is reportedly in talks with AmerisourceBergen (ABC) to purchase the rest of the company.
According to Novartis’s estimates for the US biologics market in 2016, there were ~8.4 million patients with moderate to severe psoriasis in the US.
During 3Q18, Canopy Growth increased its inventory and biological assets to a value of 108.3 Canadian dollars from 56 million Canadian dollars in 3Q17.
During 3Q18, Canopy Growth reported a non-GAAP (generally accepted accounting principles) gross margin of 58% of sales.
In a press release, Canopy Growth reported that its per gram weighted average cost before shipping and fulfillment fell 39% to 1.03 Canadian dollars.
Sales volume, mix, and selling prices are key drivers for Canopy Growth’s (WEED) sales as well as for companies (HMLSF) such as Aphria (APHQF), Aurora Cannabis (ACBFF), and MedReleaf (MEDFF).
Merck & Co. (MRK) missed Wall Street analysts’ estimates for revenues but surpassed analysts’ estimates earnings per share.
Merck & Co. reported earnings per share of $0.98 on revenues of $10.4 billion in 4Q17.